title: Chromosome aberrations in CD34-positive acute myeloid leukemia. Correlation with clinicopathologic features.
abstract: Morphologic, immunologic, and cytogenetic features were studied in 30 newly diagnosed patients with CD34-positive (CD34+) de novo acute myeloid leukemia (AML) in comparison with 30 patients with CD34-negative (CD34-) AML. Karyotype at diagnosis was abnormal in 25/30 CD34+ AML patients, of which nine had major karyotype aberrations (MAKA). Clonal chromosome changes were detected in 9/30 patients with CD34- AML. The most frequent chromosome aberration in CD34+ patients was -5/5q-, an aberration showing a strong association with the M2 FAB subtype of AML. Other recurring chromosome changes involved chromosome 16q (four cases) and chromosome 17p (three cases). Total or partial monosomy 7q was detected in three cases. Among CD34- AML, two patients had the classical t(15;17) and two had structural aberrations of 6q. Among patients with CD34+ AML, nine had MAKA in association with trilineage myelodysplasia (TMDS). TMDS was infrequent in CD34+ AML without MAKA and in CD34- AML. Complete remission (CR) was achieved in 8/30 CD34+ AML (26%), as compared with 22/30 CD34- AML (73%), and median survival was 2 months in the former group and 8 months in the latter. No patient with CD34+ AML and MAKA achieved CR, whereas 8/21 CD34+ AML without complex chromosome changes or with normal karyotype achieved CR. In conclusion, a distinct cytogenetic profile may be associated with CD34+ AML. Cytogenetic findings in CD34+ AML may be clinically relevant in that they may disclose a subset of patients with MAKA with a low CR rate.
authors.affiliation: Institute of Hematology, University of Ferrara, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Fagioli
authors.forename: A
authors.initials: A
authors.lastname: Cuneo
authors.forename: M G
authors.initials: MG
authors.lastname: Carli
authors.forename: A
authors.initials: A
authors.lastname: Bardi
authors.forename: N
authors.initials: N
authors.lastname: Piva
authors.forename: R
authors.initials: R
authors.lastname: Previati
authors.forename: G M
authors.initials: GM
authors.lastname: Rigolin
authors.forename: L
authors.initials: L
authors.lastname: Ferrari
authors.forename: R
authors.initials: R
authors.lastname: Spanedda
authors.forename: G
authors.initials: G
authors.lastname: Castoldi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015703:Antigens, CD; D018952:Antigens, CD34; D000951:Antigens, Neoplasm; D002869:Chromosome Aberrations; D002884:Chromosomes, Human, Pair 15; D002885:Chromosomes, Human, Pair 16; D002886:Chromosomes, Human, Pair 17; D002895:Chromosomes, Human, Pair 5; D002897:Chromosomes, Human, Pair 7; D006801:Humans; D016130:Immunophenotyping; D007621:Karyotyping; D015470:Leukemia, Myeloid, Acute / Q000235:genetics* / Q000276:immunology*; D008875:Middle Aged; D011379:Prognosis
chemical_list: D015703:Antigens, CD; D018952:Antigens, CD34; D000951:Antigens, Neoplasm